Ono Pharmaceutical Co., Ltd. (4528.T) fair value

ACCE thesis

Ono Pharmaceutical sells branded prescription drugs in Japan, most notably the immuno-oncology franchise built around Opdivo (nivolumab), which it co-develops and co-commercializes with Bristol Myers Squibb. Its moat is the royalty and profit-share economics on that franchise, which help explain a 73.6% gross margin and a 26.4% operating margin in a business that is otherwise a Japan-centric drugmaker. Revenue fell 8.9% in the latest period, so the near-term case rests on how fast the Opdivo royalty stream and the newer Ono-owned launches can offset the erosion from patent expiries and pricing cuts in the Japanese market. At 15.5x trailing and 14.9x forward earnings, the stock is priced for a decline that the margin profile suggests the business can absorb, though a 9.3% ROE says the capital base is large relative to what it earns. Worth a deeper look if the portfolio needs exposure to a high-margin Japanese pharma with a royalty-driven oncology franchise; the revenue trajectory is the question to resolve before anything else.